• AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells 

      Lotsberg, Maria Lie; Wnuk-Lipinska, Katarzyna; Terry, Stéphane; Tan, Tuan Zea; Lu, Ning; Trachsel-Moncho, Laura; Røsland, Gro Vatne; Siraji, Muntequa Ishtiaq; Hellesøy, Monica; Rayford, Austin James; Jacobsen, Kirstine; Ditzel, Henrik J; Vintermyr, Olav Karsten; Bivona, Trever G; Minna, John; Brekken, Rolf A; Baguley, Bruce; Micklem, David; Akslen, Lars A.; Gausdal, Gro; Simonsen, Anne; Thiery, Jean Paul; Chouaib, Salem; Lorens, James; Engelsen, Agnete (Journal article; Peer reviewed, 2020)
      Introduction Acquired cancer therapy resistance evolves under selection pressure of immune surveillance and favors mechanisms that promote drug resistance through cell survival and immune evasion. AXL receptor tyrosine ...
    • AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells 

      Li, Huiyu; Liu, Zhida; Liu, Longchao; Zhang, Hongyi; Han, Chuanhui; Girard, Luc; Park, Hyunsil; Zhang, Anli; Dong, Chunbo; Ye, Jianfeng; Rayford, Austin James; Peyton, Michael; Li, Xiaoguang; Avila, Kimberley; Cao, Xuezhi; Hu, Shuiqing; Alam, Md Maksudul; Akbay, Esra A.; Solis, Luisa M.; Behrens, Carmen; Hernandez-Ruiz, Sharia; Lu, Wei; Wistuba, Ignacio; Heymach, John V.; Chisamore, Michael; Micklem, David Robert; Gabra, Hani; Gausdal, Gro; Lorens, James; Li, Bo; Fu, Yang-Xin; Minna, John D.; Brekken, Rolf A. (Journal article; Peer reviewed, 2022)
      Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 (L) mutation into murine lung adenocarcinomas ...
    • Decoding cancer's camouflage: epithelialmesenchymal plasticity in resistance to immune checkpoint blockade 

      Lotsberg, Maria Lie; Rayford, Austin James; Thiery, Jean Paul; Bellaggia, Giuliana; Peters, Stacey D'Mello; Lorens, James; Chouaib, Salem; Terry, Stéphane; Engelsen, Agnete (Journal article, 2020)
      Epithelial-mesenchymal plasticity (EMP) of cancer cells contributes to cancer cell heterogeneity, and it is well established that EMP is a critical determinant of acquired resistance to cancer treatment modalities including ...